ライフサイエンスコーパス: HPN

1 HPN costs were euro13,276 for treatment introduction, fo

2 HPN imaging may provide a new method for detection of pr

3 HPN patients were evaluated after a mean period of 5.1 y

4 HPN-targeted imaging agents were synthesized by conjugat

5 was estimated that in 1992 there were 40,000 HPN patients and 152,000 HEN patients nationwide.

6 were compared among 10 ITx recipients and 10 HPN patients.

7 ificance (p < 5 x 10(-8)) for serum albumin (HPN-SCN1B, GCKR-FNDC4, SERPINF2-WDR81, TNFRSF11A-ZCCHC2,

8 The mean +/- SD age at HPN onset was 0.7 +/- 0.3 y, with a mean duration of 1.9

9 who may benefit from transplantation before HPN-associated secondary organ failure.

10 quality of life was markedly similar between HPN-dependent patients and ITx recipients, with signific

11 SBS was the major indication for HPN in our cohort.

12 The indications for HPN were divided into primary digestive diseases (PDDs)

13 The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), c

14 ing was associated with a poorer outcome for HPN patients, it was still reasonably good; therefore, a

15 ve identified a pair of robust marker genes (HPN and STAT6) by integrating microarray datasets from t

16 Geriatric HPN patients had a generally good outcome but did not do

17 ys have resulted in the discovery of hepsin (HPN) as a biomarker for detection of prostate cancer.

18 life in ITx recipients is similar to that in HPN-dependent patients.

19 We used phage display to isolate HPN binding peptides with 190 + 2.2 nmol/L affinity in m

20 ost strongly associated serum albumin locus, HPN, for which Hpn knockout mice manifest low plasma alb

21 absorption, which is associated with a lower HPN dependence.

22 When injected into mouse xenograft models, HPN-targeted nanoparticles bound specifically to HPN-exp

23 Correspondingly, most HPNs showed strong dendritic labeling for both GluR1 and

24 d cultures of hippocampal pyramidal neurons (HPNs) exposed to low pH (acidosis).

25 ) channels on hippocampal pyramidal neurons (HPNs) has been controversial, although they are present

26 xpressing LNCaP xenografts compared with non-HPN-expressing PC3 xenografts.

27 Home parenteral nutrition (HPN) and intestinal transplantation (ITx) are the 2 trea

28 nt absorption and home parenteral nutrition (HPN) dependence in SBS patients with intestinal failure.

29 e indications for home parenteral nutrition (HPN) in children and describe the outcome over a 14-y pe

30 failure receiving home parenteral nutrition (HPN) to that among patients who underwent intestinal tra

31 and dependency on home parenteral nutrition (HPN).

32 The major complications of HPN were catheter-related bloodstream infections (CRBSIs

33 In this study, we explore the development of HPN imaging probes for detection of prostate cancer.

34 ber 2013, 52% of children were weaned off of HPN, 9% of the PDD subgroup had intestinal transplantati

35 In contrast, the majority of HPNs (putatively identified by morphological criteria an

36 A subpopulation of HPNs, however, displayed noticeable [Ca2+]i rises that b

37 erved in SBS children 6 mo after weaning off HPN.

38 The dependence on HPN was expressed by the number of infusions per week an

39 enty patients with CD and IF, established on HPN, were evaluated for ITx.

40 hout IR, all patients progressed to home PN (HPN).

41 cenarios, a proportion of patients receiving HPN were eventually eligible for an intestinal transplan

42 r institution and discharged while receiving HPN between 1 January 2000 and 31 December 2013.

43 nsduction case-studies, including the recent HPN-DREAM breast cancer challenge.

44 nce of Ca-A/K channels and further show that HPNs display considerable heterogeneity in terms of appa

45 Here we describe the HPN-DREAM network inference challenge, which focused on

46 e art represented by the methods used in the HPN-DREAM challenge.

47 One-quarter to one-third of the HPN group was aged > or = 65 y, depending on the underly

48 In these HPNs, levels of GluR1 relative to GluR2 were higher, and

49 targeted nanoparticles bound specifically to HPN-expressing LNCaP xenografts compared with non-HPN-ex

50 rreversible IF and both of these treatments--HPN and ITx--to estimate the cost-effectiveness of ITx.

51 hed and life-threatening complications under HPN were unresolvable.

52 compared with 684 +/- 541; P < 0.05), as was HPN dependence (33% +/- 20% compared with 48% +/- 38%; P

53 vival of patients with IF in comparison with HPN at an additional cost of euro19,529 per life-year ga

54 ith <12 mo of remaining life expectancy with HPN if they did not undergo ITx.